D-0100-2021 Class III Terminated
FDA drug recall D-0100-2021 was initiated by Teva Pharmaceuticals USA on Nov 11, 2020 and is designated Class III. Reason for recall: Superpotent Drug: High out-of-specification assay results were obtained during stability testing. The recall status is terminated (terminated Jun 24, 2021). Affected quantity: 12,088 cartons.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 25, 2020
- Initiation Date
- Nov 11, 2020
- Termination Date
- Jun 24, 2021
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 12,088 cartons
Product description
Testosterone Gel 1%, 2.5 grams per unit dose, packaged in 2.5 gram Unit-Dose Packets (NDC 0591-3216-17); 30 Unit-Dose Packets per carton (NDC 0591-3216-30), Rx only, Manufactured by: Actavis Laboratories UT, Inc., Salt Lake City, UT 84108; Distributed by: Actavis Pharma, Inc., Parsippany, NJ 07054.
Reason for recall
Superpotent Drug: High out-of-specification assay results were obtained during stability testing.
Distribution pattern
Product was distributed Nationwide in the USA.
Code information
Lot Number: 1351104, Exp 08/2021
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0100-2021
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026